$CLVT

CLARIVATE PLC (CLVT): Other Events

CLARIVATE PLC (CLVT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Clarivate Announces Pricing Terms of Offer to Purchase for Cash Certain of its Outstanding Debt Securities LONDON, September 23, 2026: Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced the Reference Yi

Original reporting
Published Sep 23, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CLVT
Neutral
high confidence
Mentioned
$CLVT
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CLVTNeutralHigh
01

Why it matters

The tender offer provides a clear, time‑sensitive decision point for bondholders and may affect CLVT's equity valuation.

02

Market read

Primary relevance to CLVT investors; secondary relevance to fixed‑income market participants monitoring corporate tender offers.

03

What to watch

Potential for the tender cap to be adjusted before expiration, which could change the scale of the impact.

Relevance 8/10Novelty 8/10Timing: today, Sep 23 2026

Background

Clarivate plc (NYSE: CLVT) filed an 8‑K reporting a cash tender offer by its subsidiary to purchase a portion of its outstanding senior secured notes.

Company-level read

Ticker impact

$CLVTNeutralHigh confidence
Context

Clarivate announced pricing and terms for a cash tender offer to purchase up to $75M of its 3.875% Senior Secured Notes due 2028.

Expected impact

Potential modest downside for CLVT equity if market views the tender as a cash outflow; bond prices may tighten.

Evidence & confidence

The offer is a fresh, material corporate action with a $75M cap, disclosed for the first time via an 8‑K filing, giving traders a clear decision point today.

Market effects

May influence the broader corporate bond market as other issuers' tender offers are evaluated.

Limited to US and European investors holding Clarivate debt.

Low global impact; primarily relevant to fixed‑income traders and CLVT shareholders.

Counterpoint

If the tender is seen as a sign of cash strain, short positions on CLVT equity could be justified.

Key entities

  • Clarivate Science Holdings Corporation

    Entity executing the tender offer on behalf of Clarivate.

  • Citigroup Global Markets Inc.

    Acting as dealer manager for the tender offer.

Related articles

$CLVTMed

Clarivate Plc: Clarivate Commences Offer to Purchase for Cash Certain of its Outstanding Debt Securities

Clarivate Plc (NYSE: CLVT) announced a cash tender offer to purchase up to $75M of its 3.875% Senior Secured Notes due 2028. The offer, managed by Citigroup, expires on September 23, 2026, with a settlement date of September 25, 2026. The total consideration is based on a fixed spread and reference yield, with accrued interest also payable.

$CLVTHigh

CLARIVATE PLC (CLVT): Other Events

CLARIVATE PLC (CLVT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Clarivate Commences Offer to Purchase for Cash Certain of its Outstanding Debt Securities LONDON, September 17, 2026: Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its wholly-owned subsidiary,

$CLVTMed

Clarivate Plc Q2 2026 Earnings Call Summary

Clarivate Plc (Q2 2026) discussed its Value Creation Plan to shift from transactional to recurring subscription revenue. It plans to divest the Life Sciences & Healthcare segment by year-end 2026, targeting about 92% recurring revenue pro forma. Management cited a $269m non-cash impairment, $70m one-time costs, and expects low-end FCF due to transaction and restructuring costs.

$CLVTMed

Clarivate Reports Second Quarter 2026 Results

Clarivate Plc (NYSE: CLVT) reported Q2 2026 results for the quarter ended June 30. Total revenue fell to $587.3 million from $621.4 million a year earlier, while organic revenues declined 1.5%. Net loss widened to $268.6 million due to a $221.7 million goodwill impairment; adjusted net income was $123.1 million. The company reaffirmed its 2026 outlook and cited a Life Sciences & Healthcare divestiture.

$CLVTMedAI 8/10

CLARIVATE PLC (CLVT): Results of Operations and Financial Condition

CLARIVATE PLC (CLVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. 1 Clarivate Reports Second Quarter 2026 Results — Delivers continued progress on strategic and financial priorities through Value Creation Plan — — Sharpens focus and enhances financial profile with previously announced Life Sciences & Healthcare segment divestiture — — Reaffirms